1Konya J, Diller J. Immumity to oncogenic human papillomavizuses[J]. Cancer Res,2001,82:205-238.
2Stanley MA. Immunobiology of papillomavims infections[ J] .J Reprod Immunol,2001,52:45-49.
3Nakagawa M,Stites DP, Palefsky JM, et al. CDC-positive and CD8-positive cytotoxic T lymphocytes contribute to human papilomavirus type 16 E6 and E7 responses[J]. Clin Diagn Lab Immunol, 1999,6:494-498.
4Youde SJ, Dunbar PR, Evans EM,et al. Use of fluorogenic histocompatibility leukocyte anfigen-A * 0201/HPV 16 E7 pepdde complexes to isolate rare human cytotoxic T-lymphocyte-recognizting endogenous human papillomavims antigens[J]. Cancer Res,2000,60:365-371.
5Hagensee ME,Koutsky LA,Lee SK, et al. Detection of cervical antibodies to human papillomavims type 16 ( HPV- 16 )antigens in relation to detection of HPV-16 DNA and cervical lesions[J] .J Infect Dis,2000,181 : 1234-1239.
6Kawana K, Yasugi T, Kanda T, et al. Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia[J]. Biochem Biophys Res Commun,2002,296:1{)2-105.
7Fausch SC, Silva DM,Rudolf MP,et al. Human papillomavirus vires-like pericles do not activate langerhans cells:a possible immune escape mechanism used by human papillomaviruses[J] .J Immunol,2002,169:3242-3249.
8Giannini SL, Hubert P, Doyen J, et al. Influence of the mucosal epithelium microenvironment on langerhans cells: impllcation for the devdopmenm of squamous intraepithelial lesions of the cervix[J] .Int J Cancer,2002,97:654-659.
9Georgopoulos NT, Proffitt JL, Blair GE. Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain, TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b, 16 and 18 E7 oncoproteins[J].Oncogene,2000,19:4930-4935.
10Vambutas A, DeVoti J,Pinn W, et al. Interaction of human papillomavirus type 11 E7 protein with Tap-1 results in the reduction of ATP-dependent peptide transport[J]. Clin Immunol,2001,101:94-99.
